СПОСОБ РАННЕЙ ДИАГНОСТИКИ И ПРОГНОЗИРОВАНИЯ ПРОГРЕССИРОВАНИЯ ДИАБЕТИЧЕСКОЙ И ГИПЕРТОНИЧЕСКОЙ РЕТИНОПАТИИ ПРИ СОЧЕТАННОМ ТЕЧЕНИИ САХАРНОГО ДИАБЕТА 2 ТИПА И ГИПЕРТОНИЧЕСКОЙ БОЛЕЗНИ
FIELD: medicine.SUBSTANCE: invention relates to early diagnostics of retinopathy (DR) in patients with combined course of type 2 diabetes mellitus (Type 2 DM) and hypertensiove disease (HD). Optic coherent tomography (OCT) of macular zone (MZ) of retina is performed, volume of retina thickness in 9 sectors: in fovea centralis, 3 and 5 cm from it from nasal, temporal upper and lower sides is determined. After that, change of sensitivity threshold of MZ is determined by method of fundus-microperimetry MAIA by demonstrating light stimuli into the area of fovea centralis and 3 and 5 cm around it. Level of glycated haemoglobin in patients blood plasma is determined by standard method, prekallikrein and kallikrein level indices, as well as activity of elastase from neutrophils (NE) in lacrimal fluid (LF) samples are determined by photometric method with application of chromogenic substrates. Patients systolic and diastolic arterial pressure (SAP and DAP) are measured. The following criteria are calculated on the basis of obtained data by mathematical calculations: R1, characterising expression of increase in edema volume thickness by thickness of retina in the said 9 MZ sectors R2, characterising degree of change of MZ sensitivity threshold taking into account light stimulus intensity D3, characterising the level of glycated haemoglobin (HbA1c) in blood plasma D4, characterising the level of perkallikrein in LF D5, characterising the level of kallikrein in LF D6, characterising the level of NE in LF D7, characterising the level of SAP D8, characterising the level of DAP. After that, value of DRDH criterion is calculated by formula , where R1, R2, D3, D4, D5, D6, D7, D8 are the values mentioned above. Group and risk of disease progressing are determined in accordance with generalised DRDH criterion in accordance with the following intervals: at 1.75≥DRDH>1.72 - preclinical stage of DR at 1.72≥DRDH>1.67 - non-proliferative stage of DR, low risk of progressing at 1.67≥DRDH>1
